Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
AGENT FOR ENHANCING OCULAR HYPOTENSIVE EFFECT
Document Type and Number:
WIPO Patent Application WO/2017/038856
Kind Code:
A1
Abstract:
The present invention pertains to a drug available for long-term continuous administration for preventing or treating glaucoma or ocular hypertension, said drug showing no decrease in efficacy during long-term administration and exhibiting a stable ocular hypotensive effect. The present invention pertains to a therapeutic agent for glaucoma or ocular hypertension that is to be continuously administered for a long period of time, said drug comprising an Rho kinase inhibitor, more specifically, to a therapeutic agent comprising an Rho kinase inhibitor for treating glaucoma or ocular hypertension in a patient suffering from glaucoma or ocular hypertension who has been administered with a therapeutic agent comprising the Rho kinase inhibitor for treating glaucoma or ocular hypertension continuously over a definite period of time and needs a further enhanced ocular hypotensive effect.

Inventors:
KAWAMATA KENJI (JP)
MARUO KAZUSHI (JP)
SUGANAMI HIDEKI (JP)
Application Number:
PCT/JP2016/075426
Publication Date:
March 09, 2017
Filing Date:
August 31, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KOWA CO (JP)
International Classes:
A61K45/00; A61K31/551; A61P27/02; A61P27/06; A61P43/00
Other References:
TANIHARA, H. ET AL.: "One-year clinical evaluation of 0.4% ripasudil(K-115) in patients with open-angle glaucoma and ocular hypertention", ACTA OPHTHALMOLOGICA, vol. 94, 2016, pages e26 - e34, XP 055516913, ISSN: 1755-3768, [retrieved on 20150900]
HIDENOBU TANIHARA ET AL.: "ROCK Sogaiyaku Ripasudil Tengan'eki 0.4% no 52 Shukan Tenganji no Gan'atsu Kako Koka to Anzensei (Dai 3-so Choki Toyo Shiken", 26TH ANNUAL MEETING OF JAPAN GLAUCOMA SOCIETY, September 2015 (2015-09-01), pages 122, XP 009510251
HONJO, M. ET AL.: "Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 42, no. 1, 2001, pages 137 - 144, XP 002343585, ISSN: 1552-5783
FUMIO AKITA: "Ryokunaisho · Ko Gan'atsusho Chiryozai Rho Kinase Sogaiyaku (Glanatec Tengan'eki 0.4%) [Glaucoma • Rho kinase inhibitor for ocular hypertension treatment (Granatec ophthalmic solution 0. 4%),]", CHIBA-KEN YAKUSHI [CHIBA PREFECTURE MEDICINE JOURNAL], vol. 61, no. 8, 1 August 2015 (2015-08-01), pages 27 - 31, XP009509669, ISSN: 2433-4235
RAO, V. ET AL.: "Topical Application of Rho Kinase Inhibitor Decreases Intraocular Pressure and Prevents the Loss of Retinal Ganglion Cells in the Aging DBA/2J Mice", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 52, 2011, pages 3080, XP 009508860, ISSN: 1552-5783
See also references of EP 3345622A4
Attorney, Agent or Firm:
SAEKI, Takuro et al. (JP)
Download PDF: